Literature DB >> 11983699

Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog.

David J Solecki1, Matthias Gromeier, Steffen Mueller, Günter Bernhardt, Eckard Wimmer.   

Abstract

The human poliovirus receptor/CD155 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. The ectodomain of CD155 mediates cell attachment to the extracellular matrix molecule vitronectin, while its intracellular domain interacts with the dynein light chain Tctex-1. CD155 is a primate-restricted gene that is expressed during development in mesenchymal tissues and ventrally derived structures within the CNS. Its function in adults is as yet unknown, but significantly, CD155 is aberrantly expressed in neuroectodermal tumors. We show that the expression of CD155 mRNA is up-regulated when human Ntera2 cells are treated with purified Sonic hedgehog (Shh) protein. Reporter gene expression driven by the CD155 core promoter is activated by Shh in transient co-transfection assays. Analysis of the CD155 core promoter indicates that an intact GLI binding site is required for Shh activation. In addition, overexpression of Gli1 or Gli3 potently activates reporter gene expression driven by the CD155 core promoter. These data identify the CD155 gene as a transcriptional target of Shh, a finding that has significance for the normal function of CD155 during development and the expression of CD155 in neuroectodermal tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983699     DOI: 10.1074/jbc.M201378200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.

Authors:  Christian Goetz; Matthias Gromeier
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-17       Impact factor: 7.638

2.  Polio, still lurking in the shadows.

Authors:  Anthony N van den Pol
Journal:  J Neurosci       Date:  2013-01-16       Impact factor: 6.167

3.  Oncolytic poliovirus against malignant glioma.

Authors:  Christian Goetz; Elena Dobrikova; Mayya Shveygert; Mikhail Dobrikov; Matthias Gromeier
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

Review 4.  Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.

Authors:  Hauke Stamm; Jasmin Wellbrock; Walter Fiedler
Journal:  Mamm Genome       Date:  2018-08-21       Impact factor: 2.957

5.  Cancer stemness, intratumoral heterogeneity, and immune response across cancers.

Authors:  Alex Miranda; Phineas T Hamilton; Allen W Zhang; Swetansu Pattnaik; Etienne Becht; Artur Mezheyeuski; Jarle Bruun; Patrick Micke; Aurélien de Reynies; Brad H Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-17       Impact factor: 11.205

Review 6.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

7.  Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.

Authors:  Xiaoyi Yang; Eying Chen; Hengguang Jiang; Karen Muszynski; Raymond D Harris; Steven L Giardina; Matthias Gromeier; Gautam Mitra; Gopalan Soman
Journal:  J Virol Methods       Date:  2008-11-08       Impact factor: 2.014

8.  Poliovirus receptor CD155-targeted oncolysis of glioma.

Authors:  Melinda K Merrill; Guenter Bernhardt; John H Sampson; Carol J Wikstrand; Darell D Bigner; Matthias Gromeier
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

Review 9.  TIGIT as an emerging immune checkpoint.

Authors:  H Harjunpää; C Guillerey
Journal:  Clin Exp Immunol       Date:  2019-12-25       Impact factor: 4.330

10.  Non-consensus GLI binding sites in Hedgehog target gene regulation.

Authors:  Martina Winklmayr; Carmen Schmid; Sandra Laner-Plamberger; Alexandra Kaser; Fritz Aberger; Thomas Eichberger; Anna-Maria Frischauf
Journal:  BMC Mol Biol       Date:  2010-01-13       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.